On the basis of the rationale that MDSCs, like the development of AML, arise from defects in myeloid differentiation at similar progenitor stages, we reasoned that DHODH inhibitors that target MDSC biogenesis at the GMP stage would enhance myeloid cell maturation, thereby reducing MDSC burden. The gene discussed is DHODH; the disease is acute myeloid leukemia.